Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2023-11-09 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
向不特定对象发行可转换公司债券预案（四次修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "预案" (proposal or plan) for the issuance of convertible corporate bonds by Yifeng Pharmacy Chain Co., Ltd. It is a detailed issuance plan including terms of the convertible bonds, issuance scale, interest rates, conversion price adjustments, redemption and repurchase clauses, use of proceeds, and financial data for recent years. The document is not a simple announcement but a comprehensive plan and explanatory document related to a capital raising activity through convertible bonds. It includes detailed financial statements and management discussion relevant to the issuance. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. It is not an Annual Report (10-K), Audit Report (AR), or Earnings Release (ER), nor is it a regulatory announcement or proxy statement. Therefore, the correct classification is CAP with high confidence.
2023-11-09 Chinese
益丰药房第四届监事会第二十九次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Yifeng Pharmacy Chain Co., Ltd. It details the approval of various proposals related to the adjustment of the company's convertible bond issuance project and fundraising amount. The document includes voting results and procedural details of the Supervisory Board meeting held on November 9, 2023. It is not a full financial report, earnings release, or management discussion, but rather a formal announcement of meeting resolutions and approvals related to capital raising activities. The content focuses on financing adjustments and approvals, which aligns with the category of Capital/Financing Update (CAP). The document length is 2483 characters, which is relatively short but contains substantive content about financing decisions, not merely an announcement of a report publication or a regulatory filing. Therefore, the best classification is Capital/Financing Update (CAP).
2023-11-09 Chinese
益丰药房关于公司向不特定对象发行可转换公司债券的上市委会议意见落实函回复报告的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding its response to a regulatory inquiry from the Shanghai Stock Exchange about the issuance of convertible bonds to unspecified investors. It references a regulatory letter and the company's reply report filed on the exchange's website. The document does not contain financial statements or detailed financial data but rather informs about the regulatory process and the company's compliance. It is an update on a capital raising activity and regulatory approval process, not the actual issuance or detailed financial report. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report but providing a regulatory update on financing.
2023-11-07 Chinese
关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券申请的上市委会议意见落实函的回复
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from a company and its sponsor regarding an administrative penalty related to a specific store's alleged violation involving medical insurance funds. It discusses regulatory compliance, legal opinions, internal controls, and the impact of the penalty on the company. The document references the company's application for issuing convertible bonds to unspecified investors and addresses regulatory concerns raised by a listing committee. It includes statements from the company's chairman and the sponsor's chairman confirming the accuracy and completeness of the response. The document is not a financial report, earnings release, or audit report. It is a regulatory compliance and legal response document related to a capital market issuance process. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not a proxy statement, voting result, or AGM material. It is not a merger or acquisition filing. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory compliance response to a listing committee's inquiry about a company's issuance application and related legal and regulatory matters. The document length (8279 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or report publication notice.
2023-11-07 Chinese
湖南启元律师事务所关于益丰大药房连锁股份有限公司向不特定对象发行可转换公司债券的补充法律意见书（七）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's issuance of convertible bonds to unspecified investors. It includes extensive legal analysis, references to regulatory feedback, administrative penalties, and compliance with securities laws. The document is not a financial report, earnings release, or management discussion, but rather a legal opinion related to a capital raising activity (issuance of convertible bonds). This fits the category of Capital/Financing Update (CAP), as it pertains to the company's financing activities and legal compliance for a bond issuance. The document length and content confirm it is not a mere announcement or certification, but a substantive legal opinion report. Therefore, the appropriate classification is CAP with high confidence.
2023-11-07 Chinese
益丰药房关于召开2023年第三季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a 2023 third quarter earnings explanation meeting (业绩说明会) by the company. It includes the meeting time, location, participants, and how investors can participate and ask questions. It references the company's 2023 third quarter report already published on October 31, 2023, but this document itself is not the report or transcript. It is a notice about the upcoming earnings call/meeting, not the actual earnings release or transcript. The document length is short (1487 characters) and it is clearly an announcement of an event related to financial results, not the results themselves. Therefore, the best fitting category is Investor Presentation (IP), as it is a detailed presentation for investors focusing on financials and company performance, or possibly Call Transcript (CT) if it were the transcript. However, since this is a notice of the meeting, not the transcript or presentation itself, it aligns best with Investor Presentation (IP) category as it is about the earnings explanation meeting. It is not a Regulatory Filing (RNS) because it is a formal announcement of an investor event, not a miscellaneous filing. It is not an Earnings Release (ER) because it does not contain financial highlights or results, only the meeting details. Hence, classify as Investor Presentation (IP) with high confidence.
2023-11-06 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.